Skip Navigation


European Heart Journal Advance Access originally published online on August 8, 2008
European Heart Journal 2008 29(18):2191-2192; doi:10.1093/eurheartj/ehn367
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
29/18/2191    most recent
ehn367v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in EHJ
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Chesebro, J. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chesebro, J. H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2008. For permissions please email: journals.permissions@oxfordjournals.org

Diabetic atherothrombosis: helpful adjunctive therapy

James H. Chesebro*

Cardiovascular Division, UMass Medical School and Memorial Medical Center, 55 Lake Ave N, Worcester, MA 01655-0002, USA

* Corresponding author: Tel: +01 904 253 2000, Fax: +01 904 953 2911, Email: chesebrj@ummhc.org

This editorial refers to ‘A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study,’{dagger} by D.J. Angiolillo et al., on page 2202

Footnotes

The opinions expressed in this article are not necessarily those of the Editors of the European Heart Journal or of the European Society of Cardiology.

The first 10% of the full text of this article appears below.

About 90% of type 2 diabetes is attributed to excess weight, which is present in 1.1 billion adults worldwide, and in westernized urban populations the prevalence of diabetes ranges from 14 to 20%.1 Diabetic patients have more cardiovascular events, which are more severe, with increased morbidity and mortality.2 Diabetes mellitus and the adequacy of glycaemic control by lifestyle and medical therapy affect atherothrombosis via alteration of arterial rheology, the arterial wall substrate and blood thrombogenicity.3,4

The rheology of blood flow in diabetics is worsened by physical obstruction and endothelial dysfunction causing vasoconstriction, which is, in part, worsened by . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in EHJ:

A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study
Dominick J. Angiolillo, Piera Capranzano, Shinya Goto, Mohammed Aslam, Bhaloo Desai, Ronald K. Charlton, Yoshie Suzuki, Lyndon C. Box, Steven B. Shoemaker, Martin M. Zenni, Luis A. Guzman, and Theodore A. Bass
EHJ 2008 29: 2202-2211. [Abstract] [FREE Full Text]